Catalyst Financial Partners’s AbbVie ABBV Stock Holding History

Catalyst Financial Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.55M	Buy	16,332 +2,099	+15%	+$466K	0.42%	36
2025 Q4	$3.25M	Buy	14,233 +785	+6%	+$179K	0.36%	35
2025 Q3	$3.11M	Buy	13,448 +267	+2%	+$54.4K	0.38%	34
2025 Q2	$2.45M	Sell	13,181 -155	-1%	-$28.8K	0.27%	38
2025 Q1	$2.79M	Buy	13,336 +504	+4%	+$98K	0.51%	30
2024 Q4	$2.28M	Buy	12,832 +363	+3%	+$66.7K	0.43%	32
2024 Q3	$2.46M	Buy	12,469 +173	+1%	+$32.3K	0.48%	31
2024 Q2	$2.11M	Buy	12,296 +1,078	+10%	+$179K	0.46%	32
2024 Q1	$1.84M	Buy	11,218 +316	+3%	+$54.5K	0.47%	31
2023 Q4	$1.69M	Buy	10,902 +296	+3%	+$43.2K	0.48%	34
2023 Q3	$1.58M	Buy	10,606 +1,767	+20%	+$259K	0.51%	32
2023 Q2	$1.19M	Sell	8,839 -440	-5%	-$64.5K	0.42%	34
2023 Q1	$1.48M	Buy	9,279 +635	+7%	+$97.1K	0.63%	27
2022 Q4	$1.4M	Buy	+8,644	New	+$1.33M	0.72%	27

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Catalyst Financial Partners's ABBV Position: Q1 2026 in Review

Catalyst Financial Partners increased its AbbVie (ABBV) stake by 15% in Q1 2026, buying an estimated $466K and bringing the position to 16,332 shares worth $3.55M. The position accounts for 0.42% of the portfolio, ranked #36.

Catalyst Financial Partners first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Catalyst Financial Partners held 16,332 shares of AbbVie worth $3.55M as of Q1 2026.
Catalyst Financial Partners bought 2,099 AbbVie shares in Q1 2026, an estimated $466K.
AbbVie made up 0.42% of Catalyst Financial Partners's portfolio in Q1 2026, its #36 holding.
Catalyst Financial Partners first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Catalyst Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.